Myocardial Infarction News and Research

RSS

ACT updates myoblast program for heart failure treatment

Advanced Cell Technology, a leader in the field of regenerative medicine, provided an update today on the status of its myoblast program. The program has successfully and safely completed Phase I human clinical trials in more than forty patients in over four independent studies.

30 Sep 2010

Women & Infants Hospital receives $2.1M NIH grant to continue work under COBRE for Perinatal Biology

Women & Infants Hospital has recently received a $2.1 million grant from the National Institutes of Health to continue work under the Center of Biomedical Research Excellence for Perinatal Biology. Of the 108 COBREs across the country, Women & Infants is the only one specifically focused on developmental research.

28 Sep 2010

DecImmune Therapeutics receives funds to improve ischemia reperfusion injury outcomes

DecImmune Therapeutics announced today that it has received a $1 million equity investment from Astellas Venture Management and has additionally been awarded $2.2 million in Phase II SBIR funding from the National Institutes of Health.

28 Sep 2010

Disparities in cardiac care begin when patients arrive at hospital emergency rooms: Study

The well-documented disparities in cardiac care may begin almost as soon as patients arrive at hospital emergency rooms. In a study published in Academic Emergency Medicine, Massachusetts General Hospital researchers report that African-American and Hispanic patients assessed for chest pain were less likely than white patients to be categorized as requiring immediate care, despite a lack of significant differences in symptoms.

27 Sep 2010

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics 2010 in Washington.

27 Sep 2010

Boston releases HORIZONS-AMI trial data

Angiotech Pharmaceuticals, Inc. announced that its corporate partner, Boston Scientific Corporation, has released three-year follow-up data from the HORIZONS-AMI trial.

27 Sep 2010

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

24 Sep 2010

New data demonstrates safety and efficacy of Resolute drug-eluting stent

Coronary artery disease, a leading cause of death and poor quality of life worldwide, runs the gamut from simple to complex, which complicates the daily practice of interventional cardiology. New clinical data from a second, large international study that enrolled "all comers," regardless of disease complexity and comorbidities, again demonstrated the strong performance of the Resolute drug-eluting stent (DES) from Medtronic, Inc. for patients across this continuum.

24 Sep 2010

Athersys presents MultiStem phase I study results at TCT Conference

Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).

23 Sep 2010

Erasmus Medical Center Professor to present LEADERS trial result at TCT symposium

Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

23 Sep 2010

Paper calls for revision of STEMI guidelines around oxygen therapy

The European Society of Cardiology welcomes a paper published today in the Journal of the American College of Cardiology highlighting concerns over the use of oxygen therapy during MI in patients with normal oxygen levels. The publication adds to calls for revision of the STEMI guidelines around oxygen therapy and for a prospective, large scale randomised trials, issues that were both first raised in a Cochrane Review published in June.

22 Sep 2010

First in-human study of robotically assisted percutaneous coronary intervention system presented at 22nd TCT

The first in-human study of a robotically assisted percutaneous coronary intervention system demonstrated that the technique was safe and feasible. The results of the study were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

22 Sep 2010

Boston Scientific reports positive data from PLATINUM Element Stent quantitative coronary angiography study

Boston Scientific Corporation today announced data from its PLATINUM QCA study, which is designed to evaluate the Company's PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent. The results provided 30-day and nine-month clinical outcomes and nine-month quantitative coronary angiography (QCA) and intravascular ultrasound (IVUS) data supporting the safety and efficacy of the PROMUS Element Stent.

22 Sep 2010

PROMUS Element Stent receives expanded indications approval for high-risk diabetic and AMI patient groups

Boston Scientific Corporation today announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE Mark approval for use in patients with diabetes and those experiencing an acute myocardial infarction (AMI), or heart attack.

21 Sep 2010

Celera receives patent on KIF6 gene variant

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy.

21 Sep 2010

Paper highlights need for new studies and guidelines around oxygen therapy during MI

The European Society of Cardiology (ESC) welcomes a paper published today in the Journal of the American College of Cardiology (JACC )(1) highlighting concerns over the use of oxygen therapy during MI in patients with normal oxygen levels. The publication adds to calls for revision of the STEMI guidelines around oxygen therapy and for a prospective, large scale randomised trials, issues that were both first raised in a Cochrane Review published in June.

21 Sep 2010

AB5000 VADs can restore normal hemodynamics in AMI cardiogenic shock patients: Report

Results from the U.S. registry of Abiomed, Inc. AB5000 patients were recently published in the September 2010 issue of The Annals of Thoracic Surgery. The paper, "Use of the AB5000TM Ventricular Assist Device in Cardiogenic Shock After Acute Myocardial Infarction (AMI)," concludes that the "results from this nationwide registry suggest that VADs can restore normal hemodynamics and support recovery of native cardiac function in the majority of survivors when conventional therapies fail."

21 Sep 2010

NQF endorses 8 outcome measures for pulmonary, cardiovascular conditions and care provided in ICU

To improve healthcare quality and give patients and providers more information about the results of care, the National Quality Forum (NQF) has endorsed eight outcome measures for pulmonary and cardiovascular conditions and care provided in the intensive care unit (ICU). This is the first in a set of patient outcome measures NQF is reviewing.

20 Sep 2010

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.

18 Sep 2010

Abbott to present two drug eluting stents data at TCT symposium

Abbott today announced the company's schedule of key data presentations at the Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., to be held Sept. 21 – 25.

17 Sep 2010

Myocardial Infarction News and Research

ACT updates myoblast program for heart failure treatment

Women & Infants Hospital receives $2.1M NIH grant to continue work under COBRE for Perinatal Biology

DecImmune Therapeutics receives funds to improve ischemia reperfusion injury outcomes

Disparities in cardiac care begin when patients arrive at hospital emergency rooms: Study

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

Boston releases HORIZONS-AMI trial data

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

New data demonstrates safety and efficacy of Resolute drug-eluting stent

Athersys presents MultiStem phase I study results at TCT Conference

Erasmus Medical Center Professor to present LEADERS trial result at TCT symposium

Paper calls for revision of STEMI guidelines around oxygen therapy

First in-human study of robotically assisted percutaneous coronary intervention system presented at 22nd TCT

Boston Scientific reports positive data from PLATINUM Element Stent quantitative coronary angiography study

PROMUS Element Stent receives expanded indications approval for high-risk diabetic and AMI patient groups

Celera receives patent on KIF6 gene variant

Paper highlights need for new studies and guidelines around oxygen therapy during MI

AB5000 VADs can restore normal hemodynamics in AMI cardiogenic shock patients: Report

NQF endorses 8 outcome measures for pulmonary, cardiovascular conditions and care provided in ICU

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

Abbott to present two drug eluting stents data at TCT symposium

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News